Home › Research › Treatments
Lecanemab over a two-year duration: Key insights from a regional specialty medical center
Shields LBE, Hust HS, Cooper GE, Kluthe T, Hart RN, Thaliath AP, Dennis BC, Freeman SW et al.. The journal of prevention of Alzheimer's disease, 2026-01-24
Topic: Risk, prevention and care in population studies
We sought to evaluate the incidence of amyloid-related imaging abnormalities) ARIA and other adverse events associated with lecanemab. Results A total of 109 (58.3 %) patients were diagnosed with MCI, and 78 (41.7 %) had mild dementia prior to starting lecanemab. The presence of baseline microbleeds was associated with a higher frequency of solitary ARIA-H, though was only marginally statistically significant (p = 0.051). Thirty-two (17.1 %) patients discontinued lecanemab, primarily due to cognitive decline associated with progressive AD (10 [31.2 %]) and ARIA progression (9 [28.1 %]). Conclusions Our findings suggest that ARIA is a significant concern especially in patients who are ε4 homozygous.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Shields, L. B. E., Hust, H. S., Cooper, G. E., Kluthe, T., Hart, R. N., Thaliath, A. P., et al. (2026). Lecanemab over a two-year duration: Key insights from a regional specialty medical center. The journal of prevention of Alzheimer's disease. https://doi.org/10.1016/j.tjpad.2026.100489
Vancouver
Shields LBE, Hust HS, Cooper GE, Kluthe T, Hart RN, Thaliath AP, et al. Lecanemab over a two-year duration: Key insights from a regional specialty medical center. The journal of prevention of Alzheimer's disease. 2026. doi:10.1016/j.tjpad.2026.100489. PMID: 41581261.
BibTeX
@article{shields2026-41581261,
author = {Shields, L. B. E. and Hust, H. S. and Cooper, G. E. and Kluthe, T. and Hart, R. N. and Thaliath, A. P. and Dennis, B. C. and Freeman, S. W. and others},
title = {{Lecanemab over a two-year duration: Key insights from a regional specialty medical center}},
journal = {The journal of prevention of Alzheimer's disease},
year = {2026},
doi = {10.1016/j.tjpad.2026.100489},
pmid = {41581261},
url = {https://doi.org/10.1016/j.tjpad.2026.100489}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- We sought to evaluate the incidence of amyloid-related imaging abnormalities) ARIA and other adverse events associated with lecanemab.
- Results A total of 109 (58.3 %) patients were diagnosed with MCI, and 78 (41.7 %) had mild dementia prior to starting lecanemab.
- The presence of baseline microbleeds was associated with a higher frequency of solitary ARIA-H, though was only marginally statistically significant (p = 0.051).
- Thirty-two (17.1 %) patients discontinued lecanemab, primarily due to cognitive decline associated with progressive AD (10 [31.2 %]) and ARIA progression (9 [28.1 %]).
- Conclusions Our findings suggest that ARIA is a significant concern especially in patients who are ε4 homozygous.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Participants187
- Evidence strengthLow
How this study scored 55/100
Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomised / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multi-centre collaboration, so those were left out: it earned 32 of the 58 points we could judge it on, which is 55 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (The journal of prevention of Alzheimer's disease) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 2 / 4 | 187 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multi-centre collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41581261) |
| Free to read | 2 / 2 | Free to read |
| Points | 32 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 32 of the 58 points we could judge it on is 55 out of 100. |
| Total | 55 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Treatments
Also tagged “key”
4 studies in the library carry the topic tag “key”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 4 tagged studies.